The differential effects of ertugliflozin on glucosuria and natriuresis biomarkers: Prespecified analyses from VERTIS CV.
David Z I CherneyFrancesco CosentinoRichard E PratleySamuel Dagogo-JackRobert FrederichMario MaldonadoJie LiuAnnpey PongChih-Chin LiuChristopher P Cannonnull nullPublished in: Diabetes, obesity & metabolism (2022)
In VERTIS CV, ertugliflozin was associated with physiologically favourable changes in glucosuria- and natriuresis-related biomarkers. Glycaemic efficacy of ertugliflozin was attenuated in patients with higher chronic kidney disease (CKD) risk. Effects on other biomarkers were consistent, regardless of CKD risk stage.